Study summary
Immunotherapy around surgery helped more people with early TNBC stay alive
86.6%alive at 5 years, vs 81.7% without pembrolizumab
What was tested
Pembrolizumab or placebo added to chemotherapy before surgery, then pembrolizumab or placebo after surgery, for stage II or III triple-negative breast cancer.
What they found
- Estimated 5-year overall survival was 86.6% with pembrolizumab vs 81.7% with placebo.
- Side effects matched the known profiles of pembrolizumab and chemotherapy.
What it means
Confirms the KEYNOTE-522 regimen as the standard for stage II and III TNBC.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.